Clinical Trial Update: An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re... [Phase 1]

View source ↗

Summary

This Phase I trial evaluated the safety and immunogenicity of different prime-boost intervals for a monovalent H5N1 influenza vaccine (A/Indonesia/05/2005) in h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza Virus H5n1 Subtype

Drugs mentioned

• H5N1 influenza vaccine, A/Indonesia/05/2005 (monovalent subunit) (Influenza vaccine, inactivated, H5N1-subunit)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Influenza A Virus, H5N1 Subtype | Phase 1 | Status: COMPLETED